Abdelhamid M. Fares

Dr. Abdelhamid M. Fares

Population, Health, and Pathobiology, North Carolina State University, Raleigh, North Carolina, USA
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 May 2022 in Egyptian Journal of Medical Human Genetics
Verified
Journal Article
Open access
PDF file
Manal S. FawzyManal S. Fawzy
Manal S. Fawzy
HAHend Ashour
Hend Ashour
ASAya Allah Ashraf Shafie
Aya Allah Ashraf Shafie
NDNesrine Ben Hadj Dahman
Nesrine Ben Hadj Dahman
Abdelhamid M. FaresAbdelhamid M. Fares
Abdelhamid M. Fares
Fatma Mohamed FouadFatma Mohamed Fouad
Fatma Mohamed Fouad
Background: The angiotensin-converting enzyme-2 (ACE2) is recognized to be the fundamental receptor of severe acute respiratory syndrome coronavirus-2 (SARS-CoV2), responsible for the worldwide Coronavirus Disease-2019 (COVID-19) epidemic. However, genetic differences between people besides racial considerations and their relation to disease susceptibility are still not fully elucidated. Main body: To uncover the role of ACE2 in COVID-19 infection, we reviewed the published studies that explore the association of COVID-19 with the functional characteristics of ACE2 and its genetic variations. Notably, emerging studies tried to determine whether the ACE2 variants and/or expression could be associated with SARS-CoV/SARS-CoV2 have conflicting results. Some researchers investigated the potential of “population-specific” ACE2 genetic variations to impact the SARS-CoV2 vulnerability and suggested no ethnicity enrichment for ACE2 polymorphisms that could influence SARS-CoV2 S-protein binding. At the same time, some studies use data mining to predict several ACE2 variants that could enhance or decline susceptibility to SARS-CoV. On the other hand, fewer studies revealed an association of ACE2 expression with COVID-19 outcome reporting higher expression levels of ACE2 in East Asians. Conclusions: ACE2 gene variants and expression may modify the deleterious consequences of SARS-CoV2 to the host cells. It is worth noting that apart from the differences in gene expression and the genetic variations of ACE2, many other environmental and/or genetic factors could modify the disease outcome, including the genes for the innate and the adaptive immune response.

10 January 2025 in Pathogens
Verified
Journal Article
Open access
PDF file
Nagwa KhaledNagwa Khaled
Nagwa Khaled
CGCarissa Elizabeth Gaghan
Carissa Elizabeth Gaghan
Abdelhamid M. FaresAbdelhamid M. Fares
Abdelhamid M. Fares
CGChrista K Goodell
Christa K Goodell
WSWilliam Alan Stanley
William Alan Stanley
IGIsabel M. Gimeno
Isabel M. Gimeno
Very virulent plus Marek’s disease virus (vv+MDV) induces severe immunosuppression in commercial chickens. In this study, we evaluated how three Gallid alphaherpesvirus 2 (GaHV-2) vaccines (CVI-988, rMd5-BAC∆Meq, and CVI-LTR) protected against two negative outcomes of vv+MDV infection: (1) reduced viability and frequency of immune cells in the spleen and (2) decreased efficacy of the CEO (chicken embryo origin) vaccine against infectious laryngotracheitis challenge. At 25 days post-infection with vv+MDV 686, all vaccines are protected against the reduced viability of splenocytes. However, there were differences in the frequency of splenic immunophenotypes among groups. Compared to the uninfected control, the frequency of B cells was reduced in the CVI-988/686 group but not in the rMd5-BAC∆Meq/686 and CVI-LTR/686 groups. T cell subset frequencies showed no difference between the negative controls and CVI-988/686; however, there was a reduction in activated CD4+ T cells in the rMd5-BAC∆Meq/686 group and in activated CD4+, activated CD8+, and γδ+ T cells in the CVI-LTR/686 group. We also demonstrated that the three vaccines protected against MDV-induced tumors, but only rMd5-BAC∆Meq and CVI-LTR protected against the negative impact of vv+MDV 648A strain on CEO vaccine efficacy. Our findings demonstrate important differences in the biology and/or mechanisms of protection of these vaccines.

17 October 2023 in Viruses
Verified
Journal Article
Open access
PDF file
CGCarissa Elizabeth Gaghan
Carissa Elizabeth Gaghan
MBMatthew Browning
Matthew Browning
Abdelhamid M. FaresAbdelhamid M. Fares
Abdelhamid M. Fares
FCFaizal Careem
Faizal Careem
IGIsabel M. Gimeno
Isabel M. Gimeno
Ravi KulkarniRavi Kulkarni
Ravi Kulkarni
Infectious laryngotracheitis (ILT) is an economically important disease in chickens. We previously showed that an in ovo adjuvantation of recombinant herpesvirus of the turkey-Laryngotracheitis (rHVT-LT) vaccine with CpG-oligonucleotides (ODN) can boost vaccine-induced responses in one-day-old broiler chickens. Here, we evaluated the protective efficacy of in ovo administered rHVT-LT + CpG-ODN vaccination against a wild-type ILT virus (ILTV) challenge at 28 days of age and assessed splenic immune gene expression as well as cellular responses. A chicken-embryo-origin (CEO)-ILT vaccine administered in water at 14 days of age was also used as a comparative control for the protection assessment. The results showed that the rHVT-LT + CpG-ODN or the CEO vaccinations provided significant protection against the ILTV challenge and that the level of protection induced by both the vaccines was statistically similar. The protected birds had a significantly upregulated expression of interferon (IFN)γ or interleukin (IL)-12 cytokine genes. Furthermore, the chickens vaccinated with the rHVT-LT + CpG-ODN or CEO vaccine had a significantly higher frequency of γδ T cells and activated CD4+ or CD8+ T cells, compared to the unvaccinated-ILTV challenge control. Collectively, our findings suggest that CpG-ODN can be used as an effective adjuvant for rHVT-LT in ovo vaccination to induce protective immunity against ILT in broiler chickens.

21 November 2025 in Vaccine
Verified
Journal Article
Open access
ABAllison C. Boone
Allison C. Boone
CGCarissa Elizabeth Gaghan
Carissa Elizabeth Gaghan
Abdelhamid M. FaresAbdelhamid M. Fares
Abdelhamid M. Fares
MBMatthew Browning
Matthew Browning
ACAneg L. Cortes
Aneg L. Cortes
IGIsabel M. Gimeno
Isabel M. Gimeno
We have previously demonstrated that in ovo vaccination with Herpesvirus of Turkey (HVT) at 18 days-of-embryonation (ED) accelerates innate and cell-mediated immunity in one-day-old meat- and egg-type chickens. We also reported differences in the splenic immunophenotypes of egg-type chickens following HVT, CVI-988, and SB-1 vaccination. In this study, using meat-type chickens, we further evaluated the effect of in ovo administration of CVI-988 or SB-1 on innate and adaptive immune responses when compared to HVT. Additionally, we also assessed the synergistic immunopotentiation effect, if any, of CVI-988 or SB-1 with HVT. Results showed that all three vaccines could significantly augment splenic frequencies of γδ T cells, CD4+CD28+, CD4+CD44+, CD8+CD28+, and CD8+CD44+ T cells compared to sham-inoculated chickens. However, vaccines differed on tissue tropism, ability to increase PHA-L driven wing-web thickness, and ability to increase the frequency of some immunophenotypes. The frequencies of activated monocytes/macrophages, CD4+CD8+ double-positive (DP) cells, and CD4+MHC-II+ cells were found significantly higher in SB-1 and HVT groups compared to sham-inoculated control. Additionally, SB-1 vaccination led to significantly increased frequency of CD4+ T cells compared to CVI-988 and control groups. Furthermore, in comparison to HVT, SB-1 induced significantly higher frequencies of activated monocytes/macrophages and DP cells, while the CVI-988 vaccination showed a significant reduction in DP cells, CD4+CD28+, and CD4+CD44+ T cells. Finally, the synergistic effect of CVI-988 and HVT was observed in relation to augmenting splenic transcription of IFN-β and IFN-γ, while no effect on the changes in splenic immunophenotypes was observed. Collectively, all three vaccines (HVT, CVI-988 and SB-1) seem to enhance innate and/or adaptive responses in day-old meat-type chickens; however, immune-synergism of these vaccines needs further investigation.

13 March 2025 in Avian Pathology
Verified
Journal Article
Closed access
FBFederico C. Bonorino
Federico C. Bonorino
JMJuan F. Francisco García García Marín
Juan F. Francisco García García Marín
Abdelhamid M. FaresAbdelhamid M. Fares
Abdelhamid M. Fares
Nagwa KhaledNagwa Khaled
Nagwa Khaled
DEDeanna Emmanuel
Deanna Emmanuel
IGIsabel M. Gimeno
Isabel M. Gimeno
High load of oncogenic Marek's disease virus (MDV) DNA in the feather pulp (FP) as early as 21 days of age is a powerful criterion to predict the outcome of Marek's disease (MD) in apparently healthy chickens. The objective of this study was to elucidate the immunopathological changes in the FP of 21-days-old chickens that had been vaccinated with CVI988 vaccine (healthy), vaccinated and challenged with a very virulent plus (vv+) MDV strain 648A (well protected), or were unvaccinated and challenged with 648A strain (not protected) when compared to non-infected naïve chickens. Oncogenic MDV DNA load, histopathological and immunohistochemical evaluation of the lesions, and immunophenotypic characterization of the infiltrates by flow cytometry was conducted. Our results demonstrate that 648A infected non-vaccinated chickens had a significant increase in the percentage of CD3+ T cells, mainly CD4 + MHC-II + cells and CD8 + MHC-II + cells, when compared to all other groups. They also had a significantly decreased number of CD8β+ T cells compared to all other groups. Infection with 648A reduced the percentage of macrophages not only in the unvaccinated group but also in the CVI988/648A group. In addition, groups that were vaccinated with CVI988, regardless of the challenge status, had higher levels of CD8β+ T cells, suggesting that the vaccine has an enhancing effect on the CTL cells. Our results showed that the load of oncogenic MDV is highly correlated with the infiltration of CD4 + MHC-II + cells and provide further confirmation that FP is indeed an appropriate sample for the early diagnosis of MD.

1 January 2019
Verified
Journal Article
Closed access
NMNagwa K. Meselhy
Nagwa K. Meselhy
MEMohamed A. Abo El-Khair
Mohamed A. Abo El-Khair
BABasem M. Ahmed
Basem M. Ahmed
SESherif A. El-Soally
Sherif A. El-Soally
Abdelhamid M. FaresAbdelhamid M. Fares
Abdelhamid M. Fares
HHHussein A. Hussein
Hussein A. Hussein